Injectable Egg-Free Influenza Vaccine 2027

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2DP26R0004

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

UNITED STATES

SourceSAM
Documents1
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued a solicitation (SPE2DP26R0004) for the procurement of an injectable, egg-free influenza vaccine for the year 2027. This opportunity is classified under NAICS code 325414, which pertains to Biological Product (except Diagnostic) Manufacturing, and is further identified by Product Service Code 6505, indicating a focus on pharmaceuticals and biologicals. The primary objective of this procurement is to secure a reliable supply of injectable influenza vaccines that are manufactured without the use of eggs, thereby accommodating individuals with egg allergies and supporting broader immunization efforts across the United States. The scope of this solicitation encompasses the production, quality assurance, and timely delivery of egg-free influenza vaccines to designated locations within the United States, ensuring readiness for the 2027 influenza season. Key requirements for this solicitation include adherence to all applicable federal regulations governing the manufacture and distribution of biological products, with a particular emphasis on safety, efficacy, and compliance with current Good Manufacturing Practices (cGMP). Offerors are expected to demonstrate proven capabilities in large-scale vaccine production, robust quality control systems, and the logistical capacity to meet the anticipated demand within the specified timeframe. The intended outcome of this procurement is to enhance the Department of Defense’s ability to protect military personnel and other eligible beneficiaries from seasonal influenza, particularly those who cannot receive egg-based vaccines. The successful contractor will be responsible for delivering a consistent and high-quality supply of injectable, egg-free influenza vaccines, in accordance with the terms and conditions outlined in the solicitation. The contracting activity is managed by DLA Troop Support, a federal office within the Defense Logistics Agency. The place of performance is within the United States. Interested parties may direct inquiries to the primary contact, Rosbert Jones ([email protected], 445-737-1254), or the secondary contact, Melissa Rios Thomas ([email protected], 445-737-8646). This solicitation is currently active, with a posting date of April 11, 2026, and a response deadline of March 12, 2026. Contractors are encouraged to review the full solicitation and any associated attachments available through the official SAM.gov opportunity listing (https://sam.gov/opp/1fd20a27335c47c2a2b09929bb9ac894/view) to ensure a comprehensive understanding of the requirements and submission procedures. No specific set-aside requirements or special considerations are indicated in the provided information. Contractors with expertise in biological product manufacturing, particularly those with experience in egg-free vaccine production, are well-positioned to evaluate this opportunity for alignment with their capabilities and strategic objectives.